China carries a substantial share of the world’s liver cancer burden. Hepatocellular carcinoma, or HCC, is the most common primary liver cancer, and many cases develop in a liver already affected by chronic hepatitis, fibrosis, or cirrhosis.
Liver cancer has long been regarded as one of the most difficult cancers to treat. That picture is changing. Surveillance can detect tumors earlier, while surgery, transplantation, ablation, interventional procedures, radiotherapy, targeted therapy, and immunotherapy are creating more individualized treatment paths. The central challenge is to identify high-risk patients before symptoms appear and bring each case to a multidisciplinary team at the right time.
Why Liver Cancer Is a Major Health Burden in China
Three major forces shape liver cancer risk in China: chronic hepatitis B, harmful alcohol use, and metabolic fatty liver disease. Hepatitis C, aflatoxin exposure, smoking, diabetes, obesity, inherited liver disorders, and other causes of cirrhosis can also contribute.
Chronic Hepatitis B
China has a large population living with chronic hepatitis B virus infection. Long-term viral activity can lead to fibrosis, cirrhosis, and liver cancer. Importantly, hepatitis B-related HCC can sometimes occur even without established cirrhosis. Antiviral treatment can reduce risk but does not eliminate it, so eligible patients still need regular surveillance.
Alcohol-Related Liver Disease
Long-term heavy alcohol consumption can cause inflammation, fibrosis, and cirrhosis. Alcohol may also interact with viral hepatitis, obesity, and diabetes to accelerate liver damage. Patients should discuss alcohol use honestly with their medical team because it affects treatment safety, liver reserve, and transplant eligibility.
Metabolic Fatty Liver Disease
Metabolic dysfunction-associated steatotic liver disease is increasingly important as obesity, insulin resistance, and diabetes become more common. Advanced fibrosis and cirrhosis are major risk states, but liver cancer can occasionally arise before cirrhosis is recognized. Managing weight, blood pressure, blood sugar, and lipids is part of long-term liver cancer prevention.
Our guide to cirrhosis, liver cancer prevention, and surveillance in Shanghai explains how chronic liver disease and cancer risk are connected.
Do Not Wait for Symptoms
Early liver cancer may cause no symptoms. Abdominal discomfort, loss of appetite, weight loss, increasing fatigue, jaundice, swelling, or abdominal fluid often appears only after the disease or underlying liver dysfunction has progressed. Symptom-based detection is therefore not a safe strategy for high-risk patients.
Surveillance is different from a one-time health check. It is a repeated program intended to find a small tumor while curative treatment may still be possible. Patients with cirrhosis and selected people with chronic hepatitis B are commonly considered for surveillance. The exact eligibility should be defined by a hepatologist or liver cancer specialist.
High-Risk Surveillance: Ultrasound and Alpha-Fetoprotein
Liver ultrasound, with or without alpha-fetoprotein blood testing, is a widely used and relatively accessible surveillance approach. Many guidelines recommend surveillance approximately every six months for eligible high-risk adults, although the timing must be individualized.
Ultrasound quality can be limited by obesity, severe fatty liver, coarse cirrhotic tissue, tumor location, or operator factors. If visualization is inadequate, or if a suspicious lesion or rising AFP is found, the physician may recommend contrast-enhanced MRI, multiphase CT, or another diagnostic pathway. AFP alone cannot diagnose or rule out liver cancer.
A practical surveillance record should include:
- The cause and stage of chronic liver disease;
- Current hepatitis B or C treatment and recent viral results;
- Previous ultrasound, CT, or MRI images, not only written reports;
- AFP trends rather than a single isolated value;
- Liver function, platelet count, kidney function, and relevant comorbidities;
- The date and result of each surveillance examination.
From “The King of Cancers” to Multiple Treatment Pathways
Liver cancer treatment is not determined by tumor size alone. Doctors must consider the number and location of tumors, vascular invasion, spread outside the liver, liver function, portal hypertension, performance status, previous treatment, and transplant eligibility. Five major treatment pillars often work together rather than in isolation.
1. Surgery and Liver Transplantation
Liver resection can offer long-term disease control or cure for selected patients whose tumor can be safely removed while preserving enough functioning liver. Liver transplantation treats both the tumor and the underlying cirrhotic liver in carefully selected patients, but eligibility, donor availability, waiting time, and medical fitness must all be considered.
At Fudan University Zhongshan Hospital, hepatobiliary teams have extensive experience in liver cancer surgery, complex resection, recurrence management, and conversion strategies. Learn more about Prof. Zhou Jian’s work in liver tumor surgery and Prof. Fan Jia’s liver cancer expertise.
2. Interventional Treatment
Transarterial chemoembolization, commonly called TACE, and other catheter-based procedures can deliver treatment through the tumor’s blood supply. These approaches may be used for selected intermediate-stage tumors, for disease control, as a bridge to transplantation, or as part of downstaging or conversion treatment.
Technique and patient selection matter. Portal vein tumor thrombus, poor liver reserve, biliary obstruction, kidney function, and previous treatment can change the risk-benefit balance. Read more about interventional treatment for liver cancer and portal hypertension in Shanghai.
3. Local Ablation
Radiofrequency ablation, microwave ablation, and other local techniques can destroy selected tumors without major open surgery. They are particularly relevant for small lesions in suitable locations and may be combined with resection or interventional treatment. Proximity to major vessels, bile ducts, the diaphragm, or other organs may affect feasibility and safety.
4. Targeted Therapy
Targeted medicines can slow tumor growth through pathways involved in blood-vessel formation and cancer signaling. The choice depends on disease stage, liver function, previous treatment, bleeding risk, blood pressure, and other medical factors. Side effects may include fatigue, hypertension, hand-foot reactions, diarrhea, appetite loss, and liver dysfunction, requiring structured monitoring.
5. Immunotherapy
Immune checkpoint inhibitors, often combined with anti-angiogenic therapy or another immunotherapy agent, have changed first-line and later-line treatment for many patients with advanced HCC. However, not every patient is suitable. Bleeding risk, varices, autoimmune disease, transplant history, viral hepatitis status, and liver function require careful assessment.
Immunotherapy may cause inflammation in the liver, lungs, bowel, thyroid, or other organs. New jaundice, severe fatigue, shortness of breath, diarrhea, fever, or abdominal symptoms should be reported promptly.
Shanghai’s Multidisciplinary Model
Zhongshan Hospital, Fudan University is a major national center for liver cancer diagnosis, treatment, clinical research, and professional training. Its hepatobiliary surgery, liver oncology, interventional radiology, radiation oncology, imaging, pathology, hepatology, and transplant teams support a comprehensive decision-making model.
Prof. Zhou Jian and colleagues have contributed to liver cancer surgery, recurrence prediction, precision classification, and conversion treatment. The practical value of this work is not a single “best” procedure. It is the ability to move patients between treatment options as the disease and liver function change.
For example, a tumor initially considered unresectable may, in selected cases, respond to systemic and local treatment sufficiently for the team to reconsider surgery. This is known as conversion therapy and requires strict assessment rather than a guarantee. Our portal vein tumor thrombus conversion-treatment case illustrates this multidisciplinary logic.
Radiotherapy and Immunotherapy: An Emerging Combination
Modern radiotherapy can deliver focused treatment to selected liver tumors, vascular tumor thrombus, or limited metastatic sites while reducing exposure to surrounding tissue. The team led by Prof. Du Shisuo has explored radiation-based strategies and their integration with systemic treatment.
Combining radiotherapy with immunotherapy is an active area of research. Radiation may alter the tumor immune environment, creating a scientific rationale for combination treatment, but the best sequence, dose, timing, and patient population are still being studied. Liver reserve and the volume of healthy liver exposed to radiation remain critical safety considerations.
Patients should view such combinations as specialist-led strategies, sometimes within clinical trials, rather than universally established treatment for every case.
Protecting Liver Function Is Part of Treating the Cancer
A powerful anticancer treatment is useful only if the patient’s remaining liver can tolerate it. Long-term management may include antiviral therapy, alcohol cessation, nutritional support, management of ascites or varices, prevention of infection, diabetes control, and review of all medicines and supplements for liver toxicity.
Patients should not start herbal products, high-dose supplements, or non-prescribed medicines without discussing them with the liver team. “Natural” does not automatically mean safe for a cirrhotic or treatment-stressed liver.
Questions for a Multidisciplinary Consultation
- Is the diagnosis confirmed by characteristic imaging, pathology, or both?
- What is the tumor stage, and how well is the liver functioning?
- Is surgery, transplantation, or ablation technically possible?
- Would interventional treatment, radiotherapy, or systemic therapy improve resectability?
- Does the patient need endoscopy or other bleeding-risk assessment before treatment?
- How will hepatitis, cirrhosis, portal hypertension, and other conditions be managed?
- What is the goal of treatment: cure, conversion, disease control, symptom relief, or a bridge to transplantation?
- When will imaging be repeated, and what would trigger a change in treatment?
For a broader review of available pathways, visit our liver cancer treatment guide for Shanghai.
How CMCS Supports International Patients in Shanghai
China Medical Concierge Shanghai (CMCS) is a health management and medical concierge company, not a hospital. We help international patients organize their medical information, identify appropriate specialists in Shanghai, and coordinate care before, during, and after appointments.
Depending on the case, CMCS can assist with:
- Organizing liver imaging, pathology, AFP trends, viral hepatitis records, liver function tests, and previous treatment details;
- Coordinating evaluation by hepatobiliary surgery, liver oncology, interventional radiology, radiation oncology, hepatology, or a multidisciplinary team;
- Preparing a concise bilingual case summary and prioritized consultation questions;
- Supporting appointment planning, travel preparation, on-site communication, and examination scheduling;
- Helping patients track treatment milestones, surveillance dates, and side-effect concerns;
- Facilitating necessary communication with family members after receiving the patient’s authorization.
Remote record review or video consultation requires the physician’s approval and may not replace an in-person examination. Patients should provide authorization and complete, recent medical records before case coordination. CMCS can usually address approximately three to five core questions during initial screening. If specific medical coordination is required, the service scope and applicable fee will be explained in advance.
Conclusion: Stop Liver Cancer Before It Reaches an Advanced Stage
The most important opportunity in liver cancer is often created before symptoms begin. Identifying high-risk patients, treating viral and metabolic liver disease, maintaining six-monthly surveillance when recommended, and investigating suspicious findings promptly can move diagnosis into an earlier and more treatable stage.
For patients already diagnosed, multidisciplinary planning can combine surgery, intervention, ablation, radiotherapy, targeted therapy, and immunotherapy according to both tumor biology and liver function. The objective is not simply to attack the tumor, but to preserve enough healthy liver to keep future treatment options open.
Contact CMCS
For help organizing liver cancer records, connecting with appropriate specialists in Shanghai, or planning a medical visit, contact us:
- Website: www.medicalsh.com
- Email: contract@medicalsh.com
- WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
You may also submit your information through our contact page.
Medical notice: This article is for health education only and does not provide a diagnosis or individualized treatment advice. Surveillance, imaging, medication, surgery, interventional procedures, radiotherapy, and follow-up plans must be determined by qualified physicians using the patient’s complete medical information.
0 comentarios